Targeting receptor tyrosine kinases in solid tumors.

Abstract

Tyrosine kinase (TK) cascades are involved in all stages of tumorigenesis through modulation of transformation and differentiation, cell-cycle progression, and motility. Advances in molecular targeted drug development allow the design and synthesis of inhibitors targeting cancer-associated signal transduction pathways. Potent selective inhibitors with low toxicity can benefit patients with local and metastatic malignancies. This article evaluates information on solid tumor-related TK signaling and inhibitors, including receptor TK signal pathways that lead to successful application in clinical settings, properties of recently approved TK-inhibitor drugs for the treatment of solid tumors, and potential TK pathways for future therapeutic interventions.

• Authors: Jianliang Zhang, Steven N Hochwald
• Journal: Surgical oncology clinics of North America (Surg Oncol Clin N Am) Vol. 22 Issue 4 Pg. 685-703 (Oct 2013) ISSN: 1558-5042 [Electronic] United States
• PMID: 24012395 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Receptor Protein-Tyrosine Kinases

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Humans
• Molecular Targeted Therapy
• Neoplasms (drug therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
• Signal Transduction (drug effects)